Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12236955 | 0.98 | SMN1; SMN2 (0.64) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| SCHEMBL10058074 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9ANPC1MAPTGAA | |
| SCHEMBL3076504 | 0.82 | NPC1 (1.00) | SMN1; SMN2RAB9ANPC1MAPTEPHX1 | |
| SCHEMBL2377367 | 0.82 | NPC1 (1.00) | SMN1; SMN2RAB9ANPC1MAPTEPHX1 | |
| SCHEMBL8165938 | 0.82 | NPC1 (1.00) | SMN1; SMN2RAB9ANPC1MAPTEPHX1 | |
| SCHEMBL23736058 | 0.82 | NPC1 (1.00) | SMN1; SMN2RAB9ANPC1MAPTEPHX1 | |
| SCHEMBL966655 | 0.82 | EPHX1 (0.72) | SMN1; SMN2RAB9ANPC1EPHX1KDM4E | |
| SCHEMBL13480593 | 0.82 | EPHX1 (0.72) | SMN1; SMN2RAB9ANPC1EPHX1KDM4E | |
| SCHEMBL13480574 | 0.82 | EPHX1 (0.72) | SMN1; SMN2RAB9ANPC1EPHX1KDM4E | |
| SCHEMBL22962173 | 0.81 | EPHX1 (0.53) | SMN1; SMN2RAB9ANPC1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100330109-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-30 | — | — | US | disclosed |
| US-7683033-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330109-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | SMN1; SMN2 1613/4885RAB9A 2028/4885NPC1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.